NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free AKRO Stock Alerts $23.98 -0.64 (-2.60%) (As of 06/14/2024 08:50 PM ET) Add Compare Share Share Today's Range$23.45▼$24.4650-Day Range$18.31▼$24.6252-Week Range$11.25▼$56.66Volume559,500 shsAverage Volume1.09 million shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$41.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Akero Therapeutics alerts: Email Address Akero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside71.5% Upside$41.13 Price TargetShort InterestHealthy10.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.29Based on 48 Articles This WeekInsider TradingSelling Shares$695,716 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.82) to ($4.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.06 out of 5 starsMedical Sector165th out of 913 stocksPharmaceutical Preparations Industry67th out of 429 stocks 4.4 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkero Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Akero Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.79% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Akero Therapeutics has recently decreased by 10.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 1.8 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 48 news articles for Akero Therapeutics this week, compared to 6 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $695,716.00 in company stock.Percentage Held by InsidersOnly 7.94% of the stock of Akero Therapeutics is held by insiders.Read more about Akero Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -7.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -7.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akero Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Akero Therapeutics Stock (NASDAQ:AKRO)Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesJune 14 at 11:33 AM | insidertrades.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 569 Shares of StockJune 14 at 10:46 AM | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $56,962.24 in StockJune 14 at 9:54 AM | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 7,894 SharesJune 6, 2024 | insidertrades.comJonathan Young Sells 5,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockJune 17 at 7:02 AM | globenewswire.comUPCOMING INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKROJune 17 at 5:00 AM | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 10.4% in MayJune 16 at 11:18 AM | globenewswire.comAKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJune 15 at 7:26 AM | americanbankingnews.comJonathan Young Sells 2,516 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockJune 15 at 7:26 AM | americanbankingnews.comCatriona Yale Sells 2,825 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockJune 14 at 3:20 PM | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 569 Shares of StockJune 14 at 12:44 PM | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $64,093.84 in StockJune 14 at 2:28 AM | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for Akero Therapeutics (NASDAQ:AKRO)June 13, 2024 | globenewswire.comAKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 13, 2024 | globenewswire.comLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmJune 13, 2024 | prnewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitJune 13, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROJune 13, 2024 | prnewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitJune 13, 2024 | americanbankingnews.comCantor Fitzgerald Weighs in on Akero Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:AKRO)June 13, 2024 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Coverage Initiated at Wolfe ResearchJune 12, 2024 | globenewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROJune 12, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsJune 12, 2024 | globenewswire.comAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 12, 2024 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Given "Buy" Rating at HC WainwrightJune 11, 2024 | globenewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROJune 11, 2024 | globenewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitSee More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/17/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$41.13 High Stock Price Target$56.00 Low Stock Price Target$30.00 Potential Upside/Downside+71.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.72% Return on Assets-25.63% Debt Debt-to-Equity Ratio0.04 Current Ratio30.12 Quick Ratio30.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.61 per share Price / Book2.50Miscellaneous Outstanding Shares69,150,000Free Float63,660,000Market Cap$1.66 billion OptionableOptionable Beta-0.31 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1.04MDr. Jonathan M. Young J.D. (Age 54)Ph.D., Co-Founder, Executive VP, COO & Secretary Comp: $672.35kDr. Timothy Rolph (Age 70)Co-Founder & Chief Scientific Officer Comp: $722.32kMr. William R. White J.D. (Age 51)Executive VP, CFO, Treasurer & Head of Corporate Development Comp: $678.06kMs. Catriona Yale (Age 52)Executive VP & Chief Development Officer Comp: $678.06kMr. Scott A. Gangloff (Age 50)Chief Technical Officer Mr. David West J.D.Vice President of LegalMr. John J. Schembri (Age 62)Vice President & Head of Finance Mr. Patrick Lamy (Age 51)Senior Vice President of Commercial Strategy More ExecutivesKey CompetitorsAlbireo PharmaNASDAQ:ALBOEnanta PharmaceuticalsNASDAQ:ENTACymaBay TherapeuticsNASDAQ:CBAYMadrigal PharmaceuticalsNASDAQ:MDGLViking TherapeuticsNASDAQ:VKTXView All CompetitorsInsiders & InstitutionsAndrew ChengSold 7,894 sharesTotal: $178,720.16 ($22.64/share)Jonathan YoungSold 2,516 sharesTotal: $56,962.24 ($22.64/share)Catriona YaleSold 2,825 sharesTotal: $63,958.00 ($22.64/share)William Richard WhiteSold 2,831 sharesTotal: $64,093.84 ($22.64/share)Patrick LamySold 569 sharesTotal: $12,882.16 ($22.64/share)View All Insider TransactionsView All Institutional Transactions AKRO Stock Analysis - Frequently Asked Questions Should I buy or sell Akero Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks. What is Akero Therapeutics' stock price target for 2024? 9 equities research analysts have issued twelve-month price objectives for Akero Therapeutics' stock. Their AKRO share price targets range from $30.00 to $56.00. On average, they predict the company's share price to reach $41.13 in the next year. This suggests a possible upside of 71.5% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts. How have AKRO shares performed in 2024? Akero Therapeutics' stock was trading at $23.35 on January 1st, 2024. Since then, AKRO shares have increased by 2.7% and is now trading at $23.98. View the best growth stocks for 2024 here. Are investors shorting Akero Therapeutics? Akero Therapeutics saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 7,460,000 shares, a decline of 10.4% from the May 15th total of 8,330,000 shares. Based on an average daily volume of 954,500 shares, the days-to-cover ratio is presently 7.8 days. View Akero Therapeutics' Short Interest. When is Akero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our AKRO earnings forecast. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings results on Friday, May, 10th. The company reported ($0.90) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.90). What ETFs hold Akero Therapeutics' stock? ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Tema Cardiovascular and Metabolics ETF (HRTS), ALPS Medical Breakthroughs ETF (SBIO).Simplify Health Care ETF (PINK) and What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS). When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (8.85%), Price T Rowe Associates Inc. MD (5.87%), Vanguard Group Inc. (5.31%), Baker BROS. Advisors LP (3.92%), Redmile Group LLC (2.69%) and Yiheng Capital Management L.P. (2.07%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Patrick Lamy, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKRO) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.